Because Pfizer-BioNTech and Moderna vaccines have been developed in record time, many wonder whether companies cut corners or compromised safety.
Two pharma companies have announced early COVID-19 vaccine trial results with over 90 per cent effectiveness. What does that mean for getting back to normal?
There are two new COVID-19 vaccines that appear to be more than 90% effective. But what are these vaccines, and how are they different from those used previously?
The funding, procurement, storage and distribution of a vaccine present huge challenges to all governments, including New Zealand's.
Moderna's shot is far easier to store and distribute than Pfizer's. But there are concerns neither vaccine performs particularly well for older people.
The recent vaccine trial results certainly look impressive, but here's how to fully interrogate what they mean.
With COVID-19 cases soaring across the US and worldwide, the need for a vaccine could not be greater. Here's where we stand on vaccine development, including positive results from Pfizer's trial.
So-called mRNA vaccines are among the frontrunners in the global race to design a COVID vaccine. But as a new technology, most nations, including Australia, lack the capacity to produce them at scale.
Both Moderna and AstraZeneca have used cutting-edge designs to reduce their vaccines' development time.
The results from the phase 1 trial are a promising first step in showing that the mRNA vaccine is a viable candidate, but there are unanswered questions and it is still early in the process.
Results from phase 1 trials of a COVID-19 mRNA vaccine created a burst of optimism. But details the company failed to release suggest it is too early to speculate whether the vaccine is effective.
Vaccine development is usually a long process. The coronavirus pandemic is forcing researchers to innovate and test potential vaccines faster than ever before.